BioNTech's Pivotal Year: 2026 Holds the Key to Its Oncology Ambitions

BioNTech shifts focus to bispecific antibodies & ADCs after mRNA cancer vaccine hurdles. With €17.2B cash, it funds 15 planned Phase 3 trials despite no 2026 oncology revenue.

BioNTech is navigating a period of profound strategic transition. With its founders preparing to depart and its mRNA cancer vaccine strategy facing significant hurdles, the biotech firm is nevertheless advancing the most ambitious clinical pipeline in its history. The success of this high-stakes bet hinges on trial data expected later this year.

A Solid Financial Base Amid Operational Shifts

The company's 2025 financial results underscore its changing structure. Annual revenue reached €2.87 billion, though a decline in COVID-19 vaccine demand led to a notably weaker fourth quarter compared to the prior year. For 2026, management projects revenues between €2.0 and €2.3 billion, alongside an adjusted R&D budget of up to €2.5 billion.

This anticipated revenue dip is cushioned by a substantial war chest of €17.2 billion in cash and marketable securities. This financial buffer provides ample runway to fund an aggressive clinical development program, even in the absence of near-term oncology product sales.

Strategic Pivot: From mRNA Vaccines to Antibody Therapies

Recent clinical setbacks have prompted a strategic realignment. The most significant update from the annual report concerns autogene cevumeran (BNT122), a personalized mRNA neoantigen vaccine developed with Roche’s Genentech. A Phase 2 trial in urothelial carcinoma was halted, with the partners citing an evolving treatment landscape. The asset had previously failed in first-line melanoma. Meanwhile, a Phase 2 study in adjuvant colorectal cancer crossed a futility boundary; while it continues, final data is now delayed from 2026 to 2027.

Consequently, the strategic focus is shifting. Bispecific antibodies and antibody-drug conjugates (ADCs) are moving to the forefront, a transition BioNTech has accelerated through multiple partnerships and acquisitions. The lead project is now Pumitamig, an anti-PD-L1 x VEGF bispecific, being developed in collaboration with Bristol Myers Squibb.

Leadership in Transition

This strategic evolution coincides with a planned leadership change. Co-founders CEO Ugur Sahin and CMO Özlem Türeci are set to leave BioNTech by the end of 2026 to establish a new mRNA-focused venture. As part of this move, BioNTech will contribute selected mRNA rights in exchange for a minority stake in the new entity. A binding agreement is targeted for mid-2026, and the search for their successors is underway.

An Expansive Yet Unproven Late-Stage Pipeline

The scale of the company's clinical expansion is striking. From just two Phase 3 programs at the start of 2025, BioNTech aims to have 15 underway by the close of 2026. Among seven planned data readouts, five are considered potentially registration-enabling, including studies for trastuzumab pamirtecan, the anti-CTLA-4 antibody gotistobart, and BNT113.

A crucial caveat remains: BioNTech anticipates no oncology revenue in 2026. Its entire late-stage pipeline must first clear regulatory hurdles before contributing to the top line.

The company's shares currently trade approximately 22% below their 52-week high of €105.90. Whether this changes depends fundamentally on whether the Phase 3 readouts in the coming months can, for the first time, deliver clinical proof for BioNTech's oncology ambitions.